EUR 1.33
(-2.21%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 3.13 Million EUR | 337.71% |
2022 | -1.31 Million EUR | -244.99% |
2021 | 909 Thousand EUR | -70.04% |
2020 | 2.74 Million EUR | 339.84% |
2019 | -1.39 Million EUR | 7.33% |
2018 | -411 Thousand EUR | 31.54% |
2017 | -2.18 Million EUR | -99.4% |
2016 | -1 Million EUR | 54.63% |
2015 | -2.33 Million EUR | -378.09% |
2014 | -593.42 Thousand EUR | -229.6% |
2013 | 334.44 Thousand EUR | 197.68% |
2012 | -429.82 Thousand EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 FY | - EUR | 337.71% |
2023 Q4 | 2.42 Million EUR | 0.0% |
2023 Q2 | 1.72 Million EUR | 0.0% |
2022 FY | - EUR | -244.99% |
2022 Q2 | -1.53 Million EUR | 0.0% |
2022 Q4 | 553 Thousand EUR | 0.0% |
2021 Q4 | 365 Thousand EUR | 0.0% |
2021 FY | - EUR | -70.04% |
2021 Q2 | 795 Thousand EUR | 0.0% |
2020 Q2 | 515 Thousand EUR | 0.0% |
2020 FY | - EUR | 339.84% |
2020 Q4 | 2.51 Million EUR | 0.0% |
2019 FY | - EUR | 7.33% |
2019 Q4 | -347 Thousand EUR | 0.0% |
2019 Q2 | -921 Thousand EUR | 0.0% |
2018 Q2 | -160 Thousand EUR | 0.0% |
2018 FY | - EUR | 31.54% |
2018 Q4 | -1.2 Million EUR | 0.0% |
2017 Q2 | -1.06 Million EUR | 0.0% |
2017 FY | - EUR | -99.4% |
2017 Q4 | -926 Thousand EUR | 0.0% |
2016 FY | - EUR | 54.63% |
2016 Q2 | -386 Thousand EUR | 0.0% |
2016 Q4 | -614 Thousand EUR | 0.0% |
2015 Q2 | -764 Thousand EUR | 0.0% |
2015 FY | - EUR | -378.09% |
2015 Q4 | -1.44 Million EUR | 0.0% |
2014 Q2 | -274.7 Thousand EUR | 0.0% |
2014 Q4 | -186.3 Thousand EUR | 0.0% |
2014 FY | - EUR | -229.6% |
2013 FY | - EUR | 197.68% |
2012 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Neolife SA | 133.43 Thousand EUR | -2247.924% |
U10 Corp | 2.91 Million EUR | -7.442% |
Roche Bobois S.A. | 92.84 Million EUR | 96.625% |
SEB SA | 913.6 Million EUR | 99.657% |
Vista Alegre Atlantis, SGPS, S.A. | 29.17 Million EUR | 89.26% |